OSE Immunotherapeutics’ Post

Connect with our team of experts to find out how we can accelerate the delivery of your cell therapies. [email protected] #cdmo #regenerativemedicine #digitalfirst #celltherapy #immunotherapy #innovation #processdevelopment #continousimprovement #gmp #clinicaltrials #atmp #advancedtherapies #personalizedmedicine #gxp #optimization #automation #bestinclass #rightfirsttime

“What should I expect to feel or see when using a Gladiator Therapeutics device?” Our technology works at the cellular level. Sensation and response to therapy will vary by individual. In some patients, the nerves will become more active as healing occurs and may cause some sensitivity. In these instances, it is appropriate to move the device adjacent to the treatment area. #GladiatorTherapeutics #FarInfrared #ActiveHealing #Therapeutic #RecoveryProcess #FAQs

T2EVOLVE's latest article on accelarating development of engineered T-cell therapies in the EU is out now! Find it here:

Autologous Cell Therapies Face the Bottleneck of Saturated Medical Facilities to Administer them to Patients: Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times hindered these cell-based treatments. As biopharma companies clear those hurdles, a larger, more systemic problem now threatens the drug class. “Hospitals across the United States are already overflowing, they’re already filled, emergency rooms are packed. And if CAR-T cells become more mainstream and as earlier lines of therapy, it will just add to the hospital burden,” David Porter, M.D., director of cell therapy and transplant at Penn Medicine. #cancer #oncology #cart #celltherapy #genetherapy #immunotherapy #cartcelltherapy #hematology #drugdiscovery #drugdevelopment #drugdelivery #medicalsciences #pharmaceutics David Porter Daina Graybosch #hospital

Although the occurrence of serious hematological (T-cell) #malignancies following CAR-T cell therapy is worrying, the current incidence among patients appears to be low, indicating that the benefits of the treatment likely outweigh the rare occurrence of these adverse events. It is crucial to accurately assess and clearly communicate this risk to patients, especially as #cellulartherapies are expanding into other areas such as #solidtumors and #autoimmune disorders. Enhancing the precision of gene and cellular therapies is essential to reduce the risk of inducing cancer while maintaining the effectiveness of these groundbreaking and potentially curative treatments for many patients. #CART #CGT #cellandGene #genetherapy #oncology #drugsafety #innovation #precisionmedicine #FDA #cancer

Join us on 16 July at 15:00 CEST for an enlightening webinar on "Advancements in inhalable nano-drug delivery systems for targeted lung therapy” organised by FIP’s Industrial Pharmacy Section. Discover the advantages of pulmonary drug delivery, learn about the challenges in delivering inhalable therapies to the lungs, and gain insights into designing drug-loaded nanoparticles for effective pulmonary applications. Don't miss this opportunity to deepen your knowledge in this cutting-edge field! https://lnkd.in/dRvPhWc6

Kite Pharma's Christopher McDonald discusses their recent #celltherapymanufacturing process change to #Yescarta that lowers Turnaround Time (TAT) from 16 to 14 days, the impact of available manufacturing capacity, and the potential for improved patient outcomes. #Apheresis #CARTcellTherapy #Tcells #Leukapheresis

Clinical Question: Does the monoclonal antibody sarilumab facilitate the tapering of glucocorticoid therapy in patients with polymyalgia rheumatica? Bottom Line: Giving patients with PMR sarilumab twice monthly for 1 year allows an accelerated tapering regimen that greatly reduces the cumulative steroid dose and increases the likelihood of remission (which was low in both groups). Neutropenia, diarrhea, and arthralgia were common adverse effects. The annual drug cost is estimated to be $18,400. The cost per additional sustained response is more than $90,000, and it is unclear what the value is of the lower cumulative dose of prednisone. Reference https://bit.ly/49hHs5k

The spectrum of medical therapies to treat COVID-19 is rapidly evolving. Here is the latest information on therapeutics: https://lnkd.in/eb_ZyCbx. #covid19 #therapeutics #factsheet #themoreyouknow